February 22, 2021
Alliance A031902: CASPAR- A phase III trial of enzalutamide and rucaparib as a novel therapy in first-line metastatic castration-resistant prostate cancer
Overview: Alliance investigator Arpit Rao, MD, of the University of Minnesota, leads this randomized, placebo-controlled phase III trial to evaluate the benefit of rucaparib and enzalutamide combination therapy versus en
January 15, 2021
ASCO 12/22/2020 Statement “COVID-19 Vaccine & Patients with Cancer" At this time, patients with cancer may be offered vaccination against COVID-19 as long as components of that vaccine are not contraindicated. The current US CDC recommendations around vaccination do not mention cancer but do discuss immunocompromised individuals. They state: “Immunocompromised individuals may st
January 11, 2021
Alliance A011801: The CompassHER2 trials (Comprehensive use of pathologic response assessment to optimize therapy in HER2-positive breast cancer) CompassHER2 residual disease (RD), a double-blinded, phase III randomized trial of T-DM1 compared with T-DM1 and tucatinib
Overview: Alliance investigator Ciara C. O'Sullivan, MB, BCh, BAO, of Mayo Clinic, leads this phase III trial that studi
